tradingkey.logo

Aurion Biotech Says Co Achieves All Primary, Secondary, And Exploratory Endpoints In Aurn001 Phase 1/2 Clara Trial At 12 Months

ReutersOct 18, 2025 6:32 PM

- Aurion Biotech Inc AURN.N:

  • AURION BIOTECH ACHIEVES ALL PRIMARY, SECONDARY, AND EXPLORATORY ENDPOINTS IN AURN001 PHASE 1/2 CLARA TRIAL AT 12 MONTHS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI